4 Week treatment for Injecting Drug Users with chronic hepatitis C A phase 4, post marketing randomized clinical open label trial comparing 4 weeks of Ledipasvir/Sofosbuvir (co-formulated) and Ribavirin against 4 weeks of Ledipasvir/Sofosbuvir (co-formulated), Ribavrin and Pegylated interferon alpha2a for injecting drug users with Chronic Hepatitis C and no liver impairment at a drug treatment center.

Trial Profile

4 Week treatment for Injecting Drug Users with chronic hepatitis C A phase 4, post marketing randomized clinical open label trial comparing 4 weeks of Ledipasvir/Sofosbuvir (co-formulated) and Ribavirin against 4 weeks of Ledipasvir/Sofosbuvir (co-formulated), Ribavrin and Pegylated interferon alpha2a for injecting drug users with Chronic Hepatitis C and no liver impairment at a drug treatment center.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms 4 WIDUC
  • Most Recent Events

    • 03 Mar 2017 Status changed from recruiting to completed.
    • 09 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top